MA42769B1 - Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 - Google Patents
Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1Info
- Publication number
- MA42769B1 MA42769B1 MA42769A MA42769A MA42769B1 MA 42769 B1 MA42769 B1 MA 42769B1 MA 42769 A MA42769 A MA 42769A MA 42769 A MA42769 A MA 42769A MA 42769 B1 MA42769 B1 MA 42769B1
- Authority
- MA
- Morocco
- Prior art keywords
- muscarinic receptor
- positive allosteric
- allosteric modulators
- compounds
- fluoroindole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
La présente invention concerne un composé de formule (i), ou des stéréoisomères et sels pharmaceutiquement acceptables en tant que modulateurs allostériques positifs du récepteur muscarinique m1. Cette invention concerne en outre des procédés de fabrication de ces composés et des compositions pharmaceutiques comprenant ces composés. Les composés selon l'invention sont utiles dans le traitement de différents troubles liés au récepteur muscarinique m1.(formule i) (i)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4809CH2015 | 2015-09-10 | ||
EP16750259.0A EP3347349B1 (fr) | 2015-09-10 | 2016-07-19 | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
PCT/IB2016/054290 WO2017042643A1 (fr) | 2015-09-10 | 2016-07-19 | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42769B1 true MA42769B1 (fr) | 2019-12-31 |
Family
ID=56618200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42769A MA42769B1 (fr) | 2015-09-10 | 2016-07-19 | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
Country Status (28)
Country | Link |
---|---|
US (1) | US10294217B2 (fr) |
EP (1) | EP3347349B1 (fr) |
JP (1) | JP6553811B2 (fr) |
KR (1) | KR102068237B1 (fr) |
CN (1) | CN108026073B (fr) |
AU (1) | AU2016320645B2 (fr) |
BR (1) | BR112018004719B1 (fr) |
CA (1) | CA2997956C (fr) |
CY (1) | CY1122321T1 (fr) |
DK (1) | DK3347349T3 (fr) |
EA (1) | EA033826B1 (fr) |
ES (1) | ES2750868T3 (fr) |
HK (1) | HK1247914A1 (fr) |
HR (1) | HRP20191869T1 (fr) |
HU (1) | HUE047056T2 (fr) |
IL (1) | IL257869A (fr) |
LT (1) | LT3347349T (fr) |
MA (1) | MA42769B1 (fr) |
MD (1) | MD3347349T2 (fr) |
ME (1) | ME03571B (fr) |
MX (1) | MX2018002821A (fr) |
NZ (1) | NZ740587A (fr) |
PL (1) | PL3347349T3 (fr) |
PT (1) | PT3347349T (fr) |
RS (1) | RS59473B1 (fr) |
SI (1) | SI3347349T1 (fr) |
WO (1) | WO2017042643A1 (fr) |
ZA (1) | ZA201801463B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020003832A (es) | 2017-10-18 | 2020-08-06 | Suven Life Sciences Ltd | Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1. |
CN111278814B (zh) * | 2017-10-27 | 2022-10-28 | 苏文生命科学有限公司 | 作为毒蕈碱m1受体正向别构调节剂的多环酰胺 |
EP4100403A4 (fr) | 2020-02-04 | 2024-01-03 | Mindset Pharma Inc. | Dérivés de 3-pyrrolidine-indole en tant qu'agents psychédéliques sérotoninergiques pour le traitement de troubles du snc |
WO2023114224A1 (fr) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combinaison de modulateurs positifs du récepteur muscarinique et de modulateurs allostériques positifs de nmda |
CN115385849B (zh) * | 2022-09-14 | 2024-01-26 | 南通瑞合达医药科技有限公司 | 一种N-Boc-3-氟-4-哌啶酮提纯的方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60123485A (ja) | 1983-12-08 | 1985-07-02 | Yoshitomi Pharmaceut Ind Ltd | インド−ル−3−カルボキサミド誘導体 |
EP1254115A2 (fr) | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires |
US8389545B2 (en) | 2005-12-05 | 2013-03-05 | Merck, Sharp & Dohme, Corp. | Quinolone M1 receptor positive allosteric modulators |
CA2770480C (fr) * | 2009-08-31 | 2014-11-18 | Merck Sharp & Dohme Corp. | Modulateurs allosteriques positifs de recepteur m1 de type pyranyl-aryl-methyl-benzoquinazolinone |
ES2575154T3 (es) | 2009-12-17 | 2016-06-24 | Merck Sharp & Dohme Corp. | Moduladores alostéricos positivos del receptor M1 de quinolina amida |
WO2011149801A1 (fr) | 2010-05-28 | 2011-12-01 | Merck Sharp & Dohme Corp. | Composés de naphthalène carboxamide, modulateurs allostériques positifs du récepteur m1 |
TW201512197A (zh) | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
EP3049391B1 (fr) * | 2013-09-27 | 2018-12-26 | F.Hoffmann-La Roche Ag | Dérivés d'indoles et indazoles |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
US9708278B2 (en) | 2013-11-27 | 2017-07-18 | Vanderbilt University | Substituted 4-benzyl-3,4-dihydro-2H-benzo[B][1,4]oxazine-2-carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor M1 |
-
2016
- 2016-07-19 MA MA42769A patent/MA42769B1/fr unknown
- 2016-07-19 PT PT167502590T patent/PT3347349T/pt unknown
- 2016-07-19 CA CA2997956A patent/CA2997956C/fr active Active
- 2016-07-19 EP EP16750259.0A patent/EP3347349B1/fr active Active
- 2016-07-19 AU AU2016320645A patent/AU2016320645B2/en active Active
- 2016-07-19 JP JP2018512868A patent/JP6553811B2/ja active Active
- 2016-07-19 MD MDE20180689 patent/MD3347349T2/ro unknown
- 2016-07-19 ME MEP-2019-288A patent/ME03571B/fr unknown
- 2016-07-19 CN CN201680052764.2A patent/CN108026073B/zh active Active
- 2016-07-19 RS RS20191328A patent/RS59473B1/sr unknown
- 2016-07-19 MX MX2018002821A patent/MX2018002821A/es unknown
- 2016-07-19 KR KR1020187009938A patent/KR102068237B1/ko active IP Right Grant
- 2016-07-19 DK DK16750259T patent/DK3347349T3/da active
- 2016-07-19 US US15/758,313 patent/US10294217B2/en active Active
- 2016-07-19 ES ES16750259T patent/ES2750868T3/es active Active
- 2016-07-19 BR BR112018004719-8A patent/BR112018004719B1/pt active IP Right Grant
- 2016-07-19 LT LT16750259T patent/LT3347349T/lt unknown
- 2016-07-19 NZ NZ740587A patent/NZ740587A/en unknown
- 2016-07-19 SI SI201630447T patent/SI3347349T1/sl unknown
- 2016-07-19 PL PL16750259T patent/PL3347349T3/pl unknown
- 2016-07-19 WO PCT/IB2016/054290 patent/WO2017042643A1/fr active Application Filing
- 2016-07-19 EA EA201890684A patent/EA033826B1/ru unknown
- 2016-07-19 HU HUE16750259A patent/HUE047056T2/hu unknown
-
2018
- 2018-03-02 ZA ZA2018/01463A patent/ZA201801463B/en unknown
- 2018-03-05 IL IL257869A patent/IL257869A/en active IP Right Grant
- 2018-06-04 HK HK18107271.5A patent/HK1247914A1/zh unknown
-
2019
- 2019-10-15 HR HRP20191869TT patent/HRP20191869T1/hr unknown
- 2019-10-16 CY CY20191101086T patent/CY1122321T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
MA49235B1 (fr) | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur | |
MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
MA45153B1 (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
MA45782B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
MA40523B1 (fr) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
MA35833B1 (fr) | Dérivés de bétuline | |
MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
MA42811A (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
MA40769B1 (fr) | Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA49127B1 (fr) | Dérivés d'indole n-substitués | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA39983B1 (fr) | Dérivés de carboxamide | |
MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
MA38854B1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique |